CHARM
2003
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity — Overall Programme
In 7,601 patients with symptomatic chronic heart failure, candesartan reduced cardiovascular death and heart-failure hospitalisation compared with placebo.
Result
Efficacy: All-cause mortality (overall programme)unadjusted HR 0.91 (95% CI 0.83-1.00) · P = 0.055
Below 1 favours candesartan, above 1 favours placebo.
- Absolute difference
- 2 points
The absolute difference is derived from the event rates.
Also reported: Covariate-adjusted HR 0.90, P=0.032); CV death and HF hospitalisations significantly reduced.
- Subtopic
- ARB
- Design
- Pooled analysis of three double-blind placebo-controlled RCTs
- Relevance
- Supporting: context rather than must-know.
- Source
- Pfeffer MA, et al. Lancet. 2003;362(9386):759-766.doi 10.1016/S0140-6736(03)14282-1
Discussion & critique
Overall all-cause mortality endpoint only borderline (significant after adjustment), and the programme pooled distinct HFrEF and HFpEF populations. Established candesartan as an ACEi alternative and add-on in HFrEF.